Psychedelics
UCSF researchers test LSD-based MM120 for generalized anxiety disorder
Rapportert av AI Bilde generert av AI Faktasjekket
UCSF neuroscientist Jennifer Mitchell and collaborators are evaluating MM120, a pharmaceutical form of LSD, as a potential treatment for generalized anxiety disorder. A randomized clinical trial published in JAMA found that a single dose reduced anxiety symptoms versus placebo, with benefits persisting up to 12 weeks in the optimal dose group, according to the study and the drug’s sponsor.
An 83-year-old woman with severe Alzheimer’s disease began speaking in full sentences and regained bladder control after taking a large dose of psilocybin. The changes occurred following a single session with the psychedelic compound derived from magic mushrooms. Researchers describe the case as dramatic but stress it is only one anecdotal report.
Rapportert av AI
President Donald Trump signed an executive order on Saturday directing federal agencies to accelerate access to psychedelic drugs like psilocybin and ibogaine for treating mental health conditions, including depression, anxiety, and PTSD. The order allocates $50 million in funding and instructs the FDA to prioritize reviews. Trump was joined by Health and Human Services Secretary Robert F. Kennedy Jr., Dr. Mehmet Oz, former Navy SEAL Marcus Luttrell, and podcast host Joe Rogan.
Researchers in Hungary have found that DMT, a natural psychoactive compound, significantly mitigates brain damage from stroke in animal models and cell cultures. The molecule restores the blood-brain barrier and curbs inflammation, potentially complementing current treatments. These discoveries, published in Science Advances, highlight DMT's therapeutic promise amid limited stroke options.